# NZeno

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nzeno

- Industry: Biotechnology
- Headquarters: Auckland, New Zealand
- Website: nzeno.nz/
- Latest round: Seed (Jul 1, 2017)
- Investors on record: 3

## About

NZeno is engaged in the innovative development of genetically modified pigs for organ transplantation, addressing critical shortages in human kidneys for patients in need.NZeno is focused on the production of genetically modified pigs whose kidneys can be used for human transplantation. The company was founded in New Zealand and has not undergone any significant pivots in its business strategy. The founder has a background in biotechnology and has previously been involved in other ventures within this field.NZeno specializes in the development and supply of genetically modified pigs that produce kidneys suitable for human transplantation. By employing advanced gene editing technology, NZeno modifies high health status New Zealand pigs to inactivate specific genes responsible for immune rejection, allowing their kidneys to be compatible with human recipients. The core product offering consists of these safe pig kidneys, which aim to address the critical shortage of human kidney donors faced by individuals suffering from End Stage Renal Disease (ESRD). The primary end users of these products are patients in need of kidney transplants, along with healthcare providers and transplant centers across regions where organ shortages are prevalent. While NZeno is based in New Zealand, its products are intended for markets globally that are experiencing acute kidney shortages, thus extending the potential impact of their innovation beyond local borders.NZeno's revenue model is structured around the sale and potential licensing of its genetically modified pig kidneys to healthcare providers and transplant facilities. The transactions typically involve direct partnerships with hospitals and transplant centers, where NZeno supplies the kidneys as a solution to meet increasing demand from patients requiring transplants. While specific pricing plans are not disclosed, the nature of the transactions suggests a potential blend of upfront payments for the kidneys and ongoing agreements based on usage or patient outcomes. This model is designed to facilitate large-scale adoption of their flagship product, the genetically edited pig kidneys, within the healthcare system, ultimately aiming to enhance patient outcomes while addressing the critical kidney organ shortage.NZeno plans to launch new products that enhance the capabilities of their genetically modified kidneys, with expected releases in the next 12 to 18 months. The company is also targeting expansion into key markets in North America and Europe by the end of 2024, as these regions face significant organ shortages. Recent funding will be utilized to support research and development initiatives, as well as to establish partnerships with transplant centers in these target markets.

## Funding rounds

- Seed, Jul 1, 2017 — New Zealand Growth Capital Partners, Cure Kids Ventures, Pacific Channel

## Investors

- New Zealand Growth Capital Partners — Seed
- Cure Kids Ventures (https://capitalatlas.ai/funds/cure-kids-ventures) — Seed
- Pacific Channel (https://capitalatlas.ai/funds/pacific-channel) — Seed